Business Insider9h
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Results from these trials are expected to define the therapeutic effects of TX45 and enable us to understand its potential role in the treatment of patients with PH-HFpEF.” About the APEX Phase 2 ...
thecardiologyadvisor.com4d
Finerenone Reduces Heart Failure Events, Improves Health Status in HFmrEF, HFpEF
Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.